aod9604 clinical trials results From BPC-157 to TB-500 to AOD-9604—the world of AOD 9604 5MG - NuRev

Decreasing overall body fat can lead to improved metabolic health, including better blood pressure, cholesterol levels, and blood sugar control

The Anti-Obesity Drug designation reflects the original research focus of the compounds development at Monash University in Australia

Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials

We will be happy to reschedule your appointment for a later date